Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

1 year ago 77

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

1. Homepage
2. Lung Cancer
3. Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC